Clinical and laboratory observations

Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G

Petruzzi, Mary Jane MD
de Alarcon, Pedro A. MD

From the Department of Pediatrics, Children's Hospital of Buffalo and the State University of New York School of Medicine and Biomedical Sciences, New York, and the Department of Pediatrics, University of Virginia Medical Center, Charlottesville.
Submitted for publication Oct. 24, 1994; accepted March 10, 1995.
Reprint requests: Mary Jane Petruzzi, MD, Department of Pediatrics, Division of Hematology/Oncology, Children's Hospital of Buffalo, 219 Bryant St., Buffalo, NY 14222.

Journal of Pediatrics 127(2):p 328-329, August 1995.

An 18-month-old black girl had progressive truncal ataxia, apsoclonus, and multifocal myoclonus associated with a nonresectable abdominal ganglioneuroblastoma. Before chemotherapy, she received intravenously administered IgG, 1 gm/kg, for 2 days; within 48 hours of the first dose, there was significant improvement of the opsoclonus-myoclonus and ataxia. She required a 1 gm/kg maintenance dose every 4 to 6 weeks for a total of 12 doses, but is now free of symptomatic after 2 years with no therapy. (J Pediatr 1995;127:328-9)